Correlation of clinical signs and symptoms of BehÃ§etâ��s disease with mean platelet volume (MPV) and red cell distribution width (RDW) by Masoumi, M. et al.
Masoumi et al. Orphanet J Rare Dis          (2020) 15:297  
https://doi.org/10.1186/s13023-020-01588-1
RESEARCH
Correlation of clinical signs and symptoms 
of Behçet’s disease with mean platelet volume 
(MPV) and red cell distribution width (RDW)
Maryam Masoumi1* , Soraya Shadmanfar2, Fereydoun Davatchi3, Farhad Shahram3, Massoomeh Akhlagi3, 
Tahereh Faezi3, Hoda Kavosi3, Soroush Moradi2 and Javad Balasi4
Abstract 
Background: A strong correlation was previously found between mean platelet volume (MPV), red blood cell 
distribution width (RDW), and the severity of signs and symptoms in patients suffering from inflammatory and 
autoimmune diseases. The current study evaluated these correlations in patients with Behçet’s disease (BD) as well 
the relationship between MPV and RDW and disease activity score on the Iranian Behçet’s Disease Dynamic Activity 
Measurement (IBDDAM).
Methods: This cross-sectional study included 319 patients with BD for whom demographic and epidemiological 
data, IBDDAM scores, and duration of illness was recorded. Blood samples were then obtained and the relationships 
between their disease status and manifestations and their laboratory parameters were evaluated with statistical mod-
els to find possible correlations.
Results: Our analysis showed a significantly higher RDW in patients with BD who had ocular manifestations 
(p < 0.001) and oral aphthae (p = 0.004). Patients with active BD had higher RDW (p < 0.001) and MPV (p < 0.001) in 
comparison to those with currently inactive BD. Similarly, patients who had any type of ocular manifestation had 
higher RDW (p < 0.001) and MPV (p < 0.001). Regression analyses identified a statistically significant model for the 
effect of RDW and MPV in predicting active BD status (p < 0.001), as well as its significant relationship with active ocu-
lar manifestations (p < 0.001).
Conclusion: BD was found to be associated with an increase in MPV and RDW, particularly during active 
phases. RDW and MPV were also found to have predictive value for screening to detect BD activity and its ocular 
complications.
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Background
Behçet’s disease (BD) is a multisystemic, chronic, 
relapsing inflammatory disorder characterized by 
recurrent ulcerations and other clinical manifestations 
[1]. The main clinical manifestations include involve-
ment of the mucocutaneous, urogenital, locomotor, 
ocular, neurological, gastrointestinal, respiratory, and 
vascular systems [2, 3]. Among these, ocular involve-
ment is considered one of the most prevalent symptoms 
of BD [4, 5]. Disease activity in BD is clinically assessed 
with several classification scales, including the Ira-
nian Behçet’s Disease Dynamic Activity Measurement 
(IBDDAM), which evaluates disease activity accord-
ing to clinical findings during the preceding 12 months 
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[6]. However, there is still a demand for novel labora-
tory markers, not only to determine disease activity in 
patients with BD, but also to find potentially informa-
tive correlations with different signs and symptoms that 
can help to predict the disease course and prevent its 
exacerbation [7, 8]. As a result, biomarkers in blood 
samples from patients are currently receiving much 
attention in the search for possible correlations with 
diseases activity and its manifestations [9, 10].
In terms of its pathological manifestations BD repre-
sents a type of vasculitis; thanks to its specific clinical 
signs and symptoms, it is generally more easily diagnosed 
than other types of vasculitis since BD affects all vessels 
regardless of their size [11]. Although patients with BD 
may suffer from thrombosis-associated vascular involve-
ment, the exact mechanism of thrombus formation 
remains unclear. A further consideration is that endothe-
lial injury might not be solely responsible for the devel-
opment of thrombosis, since several patients who have 
presented with thrombosis lacked endothelial injury [12]. 
Some studies suggested that platelet function correlates 
with the development of thromboses in patients with BD 
[9, 10]. With an accurate determination of the relation-
ship between platelet activity and morphological features 
such as volume, mean platelet volume (MPV) might be 
able to serve as a diagnostic marker to further study the 
role of platelets in thrombosis formation [12, 13].
Mean platelet volume (MPV) is an important indica-
tor of platelet activation. It increases with an increase in 
thrombocyte production. Important alterations in vol-
ume parameters of thrombocytes may have prophylac-
tic and diagnostic importance in thrombotic events and 
prothrombotic tendency. In addition, increments in the 
platelet volume causes ischemia and infarction [14].
Red blood cell distribution width (RDW) is another 
parameter proposed to be associated with inflammatory 
processes. However, its use is mostly limited to the diag-
nosis of anemia because it is a numerical measurement 
of red blood cell (RBC) heterogeneity in volume in com-
plete blood counts [15, 16].
Several earlier studies have shown a strong correlation 
of MPV and RDW with the severity of patients’ signs 
and symptoms, particularly in individuals suffering from 
inflammatory and autoimmune diseases including BD 
[17, 18]. In addition, a few studies have evaluated these 
markers in patients with ocular manifestations of BD 
although none of them has investigated the relationship 
between MPV and RDW with disease activity based on 
activity measurement tools. Therefore, the present study 
was designed to compare MPV and RDW in patients 
with ocular BD and those with other manifestations, as 
well as the correlation of these measures with disease 
activity score according to the IBDDAM.
Methods
Patients diagnosed with BD were enrolled in this cross-
sectional study in consecutive order, regardless of the 
current activity state of their disease. Only drug-naive 
patients had been recruited in our study. Patients suffer-
ing from other autoimmune or inflammatory conditions, 
including but not limited to malignancies and endocrine 
diseases, were excluded from this study.
BD was diagnosed according to the ICBD criteria.
The Ethics Committee of Tehran University of Medi-
cal Sciences approved the study protocol, and all patients 
provided informed consent before participation. The 
IBDDAM questionnaire outcomes were used only for 
investigational purposes and had no impact on clinical 
decision making or treatment decisions.
The patients’ demographics and clinical information 
including age, gender, duration of the disease, medica-
tions used (e.g. colchicine, prednisolone, cytotoxic drugs, 
and disease-modifying anti-rheumatic drugs [DMARDs]) 
were recorded, along with IBDDAM scores [21]. The 
patients’ IBDDAM scores were obtained in two follow-up 
sessions, and the overall score was calculated by adding 
the scores from the two sessions and dividing the sum 
by the interval between the two sessions (in months). 
The IBDDAM score evaluates 11 clinical manifestations, 
including oral aphthae (one point per five ulcers), genital 
ulceration (one point per ulcer), pseudofolliculitis (one 
point per ten lesions), erythema nodosum (one point per 
five lesions), arthritis (arthralgia one point, monoarthritis 
two points, polyarthritis three points), venous involve-
ment (thrombophlebitis one point, large vessel throm-
bosis two points), intestinal manifestations (three points 
for mild manifestations, six points for moderate to severe 
manifestations), central nervous system (CNS) manifes-
tations (one point for mild headaches, three points for 
mild CNS involvement, six points for moderate to severe 
manifestation), epididymitis (two points), and pathergy 
(one point). Then blood samples were obtained to record 
complete blood count (CBC) components. MPV and DW 
were also measured by same laboratories.
Statistical analysis
Continuous variables were reported as the 
mean ± standard deviation (SD), and percentage and 
frequency values were used to report categorical 
data. Continuous and parametric data were compared 
between groups with an independent t-test, whereas 
categorical data were analyzed with the chi-squared 
test. A point-biserial correlation was run between CBC 
parameters of MPV and RDW and the use of DMARDs. 
Preliminary analyses showed no outliers, as assessed by 
boxplot, and engagement score was normally distrib-
uted, as assessed by Shapiro–Wilk’s test (p > 0.05). In 
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addition, variances were homogeneous, as assessed by 
Levene’s test for equality of variances.
Multiple regressions were run to predict the IBD-
DAM score from MPV and RDW. Linearity was found 
in partial regression plots and a plot of studentized 
residuals against the predicted values. The independ-
ence of residuals was verified by a Durbin–Watson 
statistic of 1.873, and homoscedasticity was confirmed 
by visual inspection of a plot of studentized residuals 
versus unstandardized predicted values. No evidence 
of multicollinearity was found, given that the tolerance 
values were higher than 0.1. There were no studentized 
deleted residuals greater than ± 3 standard deviations, 
no leverage values greater than 0.2, and values for 
Cook’s distance were greater than 1. The assumption of 
normality was met, as assessed by a Q–Q Plot.
Binomial logistic regression was used to ascertain the 
effects of MPV and RDW on the likelihood that par-
ticipants had active BD and active ocular manifesta-
tion of the disease. Linearity of continuous variables for 
the logit of the dependent variable was assessed with 
the Box–Tidwell procedure. The sensitivity, specificity, 
area under the curve (AUC), and optimal cut-off values 
were determined with receiver operating characteristic 
(ROC) curves. All analyses were done with SPSS Sta-
tistics for Windows version 25.0 (IBM Corp., Armonk, 




Three hundred twenty patients with BD between 10 and 
81 years old (mean age 43.5 ± 12 years) were enrolled. Of 
these, 142 patients (44.5%) were female and 177 (55.5%) 
were male. Their medical histories indicated that 157 
patients used colchicine, 33 received prednisolone, and 
130 underwent DMARD therapy with azathioprine 
(AZA) in 123 patients, methotrexate (MTX) in 97, and 
cyclosporine (CsA) in 16. Complete blood count showed 
average values of 88.01 ± 7.20 for MCV and 13.96 ± 1.35 
for RDW.
MPV and RDW in different BD manifestations
The prevalence of different clinical manifestations of BD 
is summarized in Table 1. An independent-sample t-test 
was run to determine whether differences in RDW or 
MPV corresponded with the appearance of specific BD 
signs and symptoms. Analyses showed that RDW was 
significantly higher only in patients with ocular mani-
festations (p < 0.001) and oral aphthae (p = 0.004). This, 
however, was not the case for MPV, and no correla-
tion was found between MPV and any disease signs or 
symptoms.
Laboratory test results were compared in patients tak-
ing different medications. In patients who were taking 
DMARDs, MPV was significantly higher than in patients 
who were not using this medication (10.78 ± 2.49 vs. 
10.17 ± 2.05, p = 0.02). There was no statistically signifi-
cant difference in RDW values between patients taking 
Table 1 Mean platelet volume (MPV) and  red blood cell distribution width (RDW) values according to  different clinical 
manifestations of Behçet’s disease
BD, Behcet’s disease; CNS, central nervous system; MPV, mean platelet volume; RDW, red blood cell distribution width; SD, standard deviation
BD manifestations Frequency (%) MPV (mean ± SD) p RDW (mean ± SD) p
Oral aphthae No 4 (1.3%) 8.9 ± 1.56 0.94 13.05 ± 0.31 0.25
Yes 315 (98.7%) 10.45 ± 2.26 13.97 ± 1.36
Genital aphthae No 137 (42.9%) 10.42 ± 2.17 0.17 13.86 ± 1.38 0.04
Yes 182 (57.1%) 10.43 ± 2.33 14.04 ± 1.34
Ocular No 68 (21.3%) 10.35 ± 1.98 0.74 13.48 ± 1.13 < 0.001
Yes 251 (78.7%) 10.45 ± 2.33 14.09 ± 1.39
Dermal No 236 (74%) 10.38 ± 2.28 0.56 14.02 ± 1.37 0.18
Yes 83 (26%) 10.55 ± 2.2 13.79 ± 1.32
Pathergy test No 200 (62.7%) 10.41 ± 2.27 0.84 14.02 ± 1.37 0.33
Yes 119 (37.3%) 10.46 ± 2.24 13.87 ± 1.35
Vascular No 294 (92.2%) 10.41 ± 2.24 0.61 13.99 ± 1.37 0.19
Yes 25 (7.8%) 10.65 ± 2.5 13.62 ± 1.14
Gastrointestinal No 305 (95.6%) 10.43 ± 2.27 0.94 13.97 ± 1.37 0.6
Yes 14 (4.4%) 10.39 ± 2.05 13.78 ± 1.04
CNS No 315 (98.7%) 10.42 ± 2.27 0.1 13.96 ± 1.36 0.62
Yes 4 (1.3%) 10 ± 0.3 13.57 ± 0.25
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and not taking DMARDs (14.11 ± 1.39 vs. 13.85 ± 1.32, 
p = 0.09).
Active BD manifestations
The frequencies of different manifestations of active BD 
are listed in Table  2. One hundred sixty-one patients 
(50.4%) were found to have active BD manifestations 
in their most recent examination. Among 109 (31.4%) 
patients with active ocular involvement, anterior uveitis 
was observed in 94 (29.5%), and posterior uveitis in 17 
(5.4%). Retinal vasculitis was seen in 58 (18.2%) patients. 
Active oral aphthae were present in 59 patients (18.5%), 
and genital aphthae were found in 9 (2.8%). Patients 
with active BD had significantly higher RDW (p < 0.001) 
and MPV (p < 0.001) in comparison to patients without 
any active manifestation (Fig. 1). Similarly, patients who 
had ocular manifestations in any site of involvement had 
higher RDW (p < 0.001) and MPV (p < 0.001) (Fig. 2). The 
presence of other BD manifestations, however, was not 
associated with MPV or RDW values in comparisons of 
patients with active BD vs. those whose disease was in an 
inactive state.
Predictive value of RDW and MPV for BD manifestations
Separate binomial logistic regression analyses were used 
to determine whether RDW and MPV could indicate 
the likelihood of patients having active BD or having 
active ocular manifestations of the disease. The results 
produced a statistically significant logistic regression 
model in which the weight of RDW and MPV had some 
predictive power for active BD status, with χ2 (2) = 82.205 
and p < 0.001. The model explained 31.0% (Nagelkerke 
R2) of the variance in BD, and correctly classified 68.3% 
of cases. Sensitivity was 80% and specificity was 51%, 
with a positive predictive value of 62% and a negative 
predictive value of 71%. Both of these two predictor vari-
ables were statistically significant (Table 3). Higher RDW 
and MPV were associated with a higher potential inci-
dence of BD. The area under the ROC curve was 0.785 
(95% confidence interval [CI] 0.737–0.834), which is con-
sidered an acceptable level of discrimination.
The highest rates of sensitivity and specificity derived 
using Youden’s J were found for the cut-off points of diag-
nostic accuracy for RDW and MPV. The RDW value of 
14.15 showed 77% sensitivity and 65% specificity for the 
diagnosis of active BD. The cut-off value of MPV was 
12.95, with 73% sensitivity and 63% specificity.
The relationship between RDW and MPV and active 
ocular manifestations was evaluated with binomial 
logistic regression. The results yielded a statistically sig-
nificant model, with χ2 (2) = 76.948 and p < 0.001. The 
model explained 29.6% (Nagelkerke R2) of the variance in 
active ocular manifestations of BD, and correctly classi-
fied 77.7% of patients. Sensitivity was 53%, specificity was 
90%, positive predictive value was 74%, and negative pre-
dictive value was 79%. In the predictive model, RDW and 
Fig. 1 Receiver operating curve of red cell distribution width (RDW) 
and mean platelet volume (MPV) in patients diagnosed with active 
Behçet’s disease
Fig. 2 Receiver operating curve of red cell distribution width (RDW) 
and mean platelet volume (MPV) in patients diagnosed with active 
ocular manifestations of Behçet’s disease
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MPV were statistically significant (Table 3), with higher 
values indicating the potential incidence of active ocular 
manifestations of BD. The area under the ROC curve was 
0.794 (95% CI 0.737–0.850), which was considered an 
acceptable level of discrimination. According to analysis 
with Youden’s J, the cut-off values for a diagnosis of active 
ocular BD were 14.93 for RDW (62% sensitivity and 92% 
specificity), and 13.42 for MPV (52% sensitivity and 90% 
specificity).
Relationship of RDW and MPV with IBDDAM score
Multiple regressions were run to predict overall IBD-
DAM score from the patients’ age, gender, body mass 
index (BMI), MPV, RDW, DMARD use, active BD status, 
active ocular signs, and active oral and genital ulcers. Six 
of the variables, e.g. age, gender, BMI, BD activity sta-
tus, and active oral and genital aphthae, had no statisti-
cally significant role in the model. After omitting these 
variables from the predictive model, partial regression 
plots revealed linearity and yielded a plot of studentized 
residuals against the predicted values. The residuals were 
independent, according to the Durbin–Watson statistic 
of 1.925. The multiple regression model showed statisti-
cally significant predictive power for IBDDAM score, 
with F (4, 314) = 26.06, p < 0.001, and adjusted  R2 = 0.24. 
All four variables added statistically significant value to 
the prediction. The regression coefficients and standard 
errors are reported in Table 4.
Discussion
The present study aimed to investigate the correlation 
between two laboratory parameters which are easily 
obtainable from a blood sample and BD activity along 
with its different manifestations. RDW was significantly 
higher in patients with ocular and oral manifestations of 
BD, regardless of disease activity. MPV, however, was not 
Table 2 Mean platelet volume (MPV) and  red blood cell distribution width (RDW) values according to  Behçet’s disease 
activity status
BD, Behçet’s disease; MPV, mean platelet volume; RDW, red blood cell distribution width; SD, standard deviation
BD active manifestations Frequency (%) MPV (mean ± SD) p RDW (mean ± SD) p
Active BD No 119 (37.4%) 9.37 ± 1.37 < 0.001 13.26 ± 0.76 < 0.001
Yes 200 (62.6%) 11.05 ± 2.45 14.38 ± 1.47
Active ocular signs No 210 (65.9%) 9.82 ± 1.84 < 0.001 13.56 ± 1.09 < 0.001
Yes 109 (34.1%) 11.59 ± 2.53 14.72 ± 1.5
Active oral signs No 206 (64.5%) 10.38 ± 2.3 0.63 13.96 ± 1.36 0.63
Yes 113 (35.5%) 10.51 ± 2.19 13.95 ± 1.36
Active genital signs No 310 (97.1%) 10.47 ± 2.26 0.87 13.96 ± 1.36 0.46
Yes 9 (2.9%) 8.94 ± 1.59 13.89 ± 1.5
Table 3 Linear regression analysis of the correlation of mean platelet volume (MPV) and red blood cell distribution width 
(RDW) with Behçet’s disease and ocular manifestations
BD, Behçet’s disease; MPV, mean platelet volume; RDW, red blood cell distribution width; SD, standard deviation
Condition Variable B SE Wald df p Odds ratio 95% CI for odds 
ratio
Lower Upper
Active BD RDW 0.709 0.131 29.362 1 < 0.001 2.031 1.572 2.625
MPV 0.32 0.07 21.221 1 < 0.001 1.378 1.202 1.579
Constant − 12.472 1.893 43.392 1 < 0.001 0
Ocular BD (active) RDW 0.584 0.112 27.382 1 < 0.001 1.793 1.441 2.232
MPV 0.289 0.063 20.993 1 < 0.001 1.335 1.18 1.511
Constant − 11.965 1.626 54.148 1 < 0.001 0
Table 4 Summary of multiple regression analysis
BD, Behçet’s disease; DMARDs, disease-modifying anti-rheumatic drugs; MPV, 
mean platelet volume; RDW, red blood cell distribution width; SE, standard error
Variable B SE beta Beta p
Intercept 30.154 8.68
RDW 2.07 0.653 0.166 0.002
MPV 0.888 0.394 0.118 0.025
Active ocular BD 4.143 1.75 0.116 0.019
DMARDs 13.793 1.704 0.4 0.001
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associated with clinical manifestations of BD. The results 
also demonstrated that RDW and MPV correlated with 
the activity of BD, particularly in patients with ocular 
manifestations. According to Aksoy et  al. study RDW 
were significantly higher in patients with Behçet’s disease 
than in controls, and in those with active disease com-
pared with inactive disease or controls. No differences 
were observed in RDW between patients with or without 
ocular or vascular involvement [19].
No such correlation was found between MPV or RDW 
and other BD signs and symptoms such as genital ulcers 
or vasculitis, probably because the incidence of these 
manifestations was low in our population sample. The 
area under the ROC curve indicated acceptable discrimi-
native ability for RDW and MPV in differentiating active 
BD and active ocular manifestations of the disease. A lin-
ear correlation was also found between overall IBDDAM 
score and the aforementioned parameters.
Since its introduction, BD diagnosis has been based 
primarily on clinical assessment and physical examina-
tion, and no specific paraclinical findings or laboratory 
tests have been especially applicable in the process [20]. 
In response to the need for better diagnostic methods 
and in order to search for a link that connects para-
clinical methods to disease activity, several biomarkers 
and factors have been identified as associated with BD 
activity, including platelet-to-lymphocyte ratio (PLR), 
neutrophil-to-lymphocyte ratio (NLR), and erythro-
cyte sedimentation rate (ESR) [21, 22]. Earlier studies 
have detected increased MPV and RDW in patients with 
inflammatory and chronic diseases, and researchers have 
speculated that these biomarkers might be associated 
with inflammation and pro-inflammatory processes [23–
25]. In this connection, RDW was found to correlate with 
levels of inflammation in rheumatoid arthritis, inflam-
matory bowel disease, and ankylosing spondylitis [16, 17, 
24, 26]. Furthermore, MPV has also been suggested as a 
biomarker associated with thrombosis and oral ulcers in 
patients with BD [27].
Since only a few studies have investigated the impor-
tance of these easily-applicable and inexpensive bio-
markers in the clinical assessment of patients with BD, 
it has not been possible to use these biomarkers in clini-
cal approaches. Nonetheless, our results show elevated 
RDW and MPV not only during BD flares but also in 
association with its ocular manifestations. Although 
the underlying etiology for this phenomenon is not well 
understood, we speculate that with the progression of 
pro-inflammatory states and the resulting disruption of 
erythropoiesis, secretion of inflammatory cytokines by 
platelets is enhanced, and an increase in RDW and MPV 
follows [12, 19]. Medication with DMARDs might also 
contribute to myelosuppression and result in disrupted 
CBC parameters such as RDW and MPV [28].
Several recent studies have noted a significant increase 
in RDW in patients with a history of BD regardless of dis-
ease activity [19, 29, 30]. Uzkeser et  al. found increased 
MPV in patients with BD compared to a healthy con-
trol group, along with a significant positive correlation 
between MPV and BD manifestations such as oral and 
genital ulcers, ocular involvement, and arthritis [31]. In 
contrast, we found no significant association between 
active oral and genital aphthae and MPV; however, we 
did find that MPV correlated with ocular involvement 
in BD. These contrasting results might be due to the low 
incidence of involvement of other organs in BD in the 
present study population.
In 2013, Turkcu et al. claimed that MPV measurement 
had no predictive value in determining the likelihood 
clinical improvement in ocular BD after standard immu-
nosuppressive treatment [32]. Although we found no sig-
nificant difference in MPV values between patients with 
and without ocular BD, the results of our study show 
not only a correlation between MPV and DMARD use, 
but also increased MPV in patients with active ocular 
involvement.
To our knowledge, our study is one of the first to eval-
uate RDW and MPV changes in patients with BD in 
connection with their disease activity and current mani-
festations. Additionally, we assessed the possible rela-
tionships of BD flares with demographic and laboratory 
characteristics, although in line with previous studies, no 
significant correlations could be found [9].
Aksoy et  al. reported in 2015 that MPV was not ele-
vated in patients with BD compared to healthy individu-
als, or in patients with active BD compared to patients 
with inactive BD, despite finding higher MPV values in 
patients with vascular involvement than those without 
[19].
It is well established that platelets play an essential role 
in various inflammatory diseases by stimulating immune 
responses and activating immune cells, which is in line 
with our finding of significantly higher MPV values in 
patient with BD, among whom the increase was higher in 
patients with active BD.
The present findings point to MPV and RDW as poten-
tially promising clinical tools in the diagnosis of BD, par-
ticularly in its active period. In addition, MPV and RDW 
might be applicable as screening parameters in patients 
with BD, although this requires further comprehensive 
research with prospective studies and randomized trials.
In light of the present results and previous finding 
regarding specific associations of NLR and PLR with the 
active phase of BD, we recommend further investigation 
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into the correlation of PLR and NLR ratios with different 
clinical manifestations of Behçet’s disease.
Limitations
The present study was not without limitations. Because 
it was carried out at a single center and conducted with a 
cross-sectional study design rather than a cohort design, 
our results provide some evidence for the applicabil-
ity of MPV and RDW as a variables able to predict the 
disease course and its manifestations, yet further stud-
ies are required to test these parameters and establish 
them as valuable tools for the diagnosis and monitoring 
of patients with BD. Another limitation of our study was 
that laboratory tests were done only once for each patient 
regardless of their clinical status or disease activity. In 
addition, the absence of data on dietary habits limited 
our results. Finally, because of the low incidence of some 
signs and symptoms of BD in our study population, we 
were not able to evaluate the involvement of all organs 
with the same level of reliability.
Conclusion
BD was found to be associated with an increase in MPV 
and RDW, particularly during active phases. RDW and 
MPV were also found to have predictive value for screen-
ing to detect BD activity and its ocular complications.
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